Type 2 diabetes (T2D) patients achieved significantly lower average A1c levels and daily insulin usage when switching to Valeritas Holdings‘ (NASDAQ:VLRX) V-Go wearable insulin delivery device.
A retrospective analysis assessed 122 T2D patients for a duration of five months after switching to V-Go from traditional insulin injection therapy.
Patients demonstrated average A1c reductions of 1.3%. Those prescribed higher baseline insulin doses 50-to-100 units per day and more than 100 units per day benefited from a total daily dose reduction of 19% and 47%, respectively. In addition, the percent of patients reporting hypoglycemia decreased on V-Go.
“We believe these results further demonstrate that, regardless of baseline insulin dose, the use of V-Go can offer patients with T2D significant clinical benefit when switching from other insulin regimens,” John Timberlake, president and CEO, said in a statement.
